HBM Partners
HBM Partners was founded in 2001 with the goal to invest in private and public emerging biopharma and other healthcare-related companies.
Business Model:
Revenue: $13.5M
Employees: 2-10
Rankings
Industries / Tags:
Detailed HBM Partners Information
Geographic Data
Address: Bundesplatz 1
City: Zug
State: zug
Zip: 6301
Country: CH
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
HBM Partners focuses on venture, growth and buy-out financings of private companies as well as investments in public companies.The HBM funds invest in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. Their team supports the growth of the portfolio companies through all stages of development, focusing on adding value by leveraging its experience and HBM&s;s world-wide network in the industry. Investments usually range between $5 million to $50 million.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2015 | Gynesonics | Venture Round | 43M |
| 3/2004 | Aspreva Pharmaceuticals Corp | Series A | 57M |
| 8/2005 | Anadys Pharmaceuticals | Private Equity Round | 71.3M |
| 12/2001 | Syrrx | Venture Round | 18.5M |
| 12/2014 | Allena Pharmaceuticals | Series B | 0 |
| 2/2013 | Gynesonics | Series D | 21M |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 3/2002 | Agensys | Series C | 0 |
| 4/2022 | Sphingotec GmbH | Convertible Note | - |
| 9/2021 | Fore Biotherapeutics | Series C | - |
| 7/2014 | Gynesonics | Debt Financing | 28.4M |
| 10/2009 | Nabriva Therapeutics | Venture Round | 0 |
| 5/2022 | Vascular Dynamics | Series D | - |
| 9/2009 | Sloning BioTechnology | Venture Round | - |
| 7/2008 | Gemin X Pharmaceuticals | Series C | 38M |
| 4/2020 | ITeos Therapeutics | Series B | 0 |
| 1/2018 | Gynesonics | Private Equity Round | 75M |
| 11/2014 | Curetis | Series B | 0 |
| 5/2015 | Symbiomix Therapeutics | Series A | 41M |
| 2/2013 | Odyssey Thera | Venture Round | 0 |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 10/2005 | Newron Pharmaceuticals | Series B | 8.4M |
| 12/2020 | Neuron23 | Series B | 80M |
| 10/2021 | Aculys Pharma | Series A | 0 |
| 12/2005 | Asthmatx | Series C | 27M |
| 10/2018 | 4TEEN4 Pharmaceuticals | Venture Round | 23M |
| 1/2004 | Cyclacel Pharmaceuticals | Series D | 38.7M |
| 10/2019 | Forbius | Series C | 2.5M |
| 3/2015 | APR Applied Pharma Research | Venture Round | - |
| 4/2022 | Farmalisto | Series B | - |
| 6/2018 | ITeos Therapeutics | Series B | 0 |
| 8/2004 | AGY Therapeutics | Series C | 9M |
| 12/2017 | Hookipa Pharma | Series C | 0 |
| 3/2022 | Neuron23 | Series C | 0 |
| 3/2022 | Aculys Pharma | Series B | 0 |
| 6/2018 | Iconic Therapeutics | Venture Round | 0 |
| 9/2020 | Monte Rosa Therapeutics | Series B | 0 |
| 5/2021 | Numab | Series C | 110.6M |
| 5/2003 | Sloning BioTechnology | Venture Round | 4.9M |
| 3/2022 | Karius | Series B | - |
| 1/2022 | Adrenomed | Convertible Note | - |
| 1/2022 | Mineralys Therapeutics | Series A | - |
| 5/2017 | connectRN | Convertible Note | 2.5M |
| 5/2015 | i-Optics | Venture Round | 15.1M |
| 6/2022 | Dren Bio | Series B | 0 |
| 1/2013 | Reha Technology | Private Equity Round | 12.9M |
| 6/2022 | Dren Bio | Series B | 0 |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 5/2022 | Odyssey Therapeutics | Series B | - |
| 5/2022 | Vascular Dynamics | Series D | - |
| 4/2022 | Farmalisto | Series B | - |
| 4/2022 | Sphingotec GmbH | Convertible Note | - |
| 3/2022 | Neuron23 | Series C | 0 |
| 3/2022 | Aculys Pharma | Series B | 0 |
| 3/2022 | Karius | Series B | - |
| 1/2022 | Mineralys Therapeutics | Series A | - |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
